Skandinaviska Enskilda Banken (SEB)’s Catalyst Pharmaceutical CPRX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-263,353	Closed	-$6.14M	–	290
2025 Q4	$6.14M	Sell	263,353 -72,147	-22%	-$1.61M	0.02%	375
2025 Q3	$6.62M	Sell	335,500 -217,200	-39%	-$4.47M	0.03%	357
2025 Q2	$12M	Sell	552,700 -234,200	-30%	-$5.53M	0.05%	263
2025 Q1	$19.1M	Buy	786,900 +55,000	+8%	+$1.24M	0.09%	181
2024 Q4	$15.4M	Buy	731,900 +312,000	+74%	+$6.7M	0.07%	208
2024 Q3	$8.35M	Buy	+419,900	New	+$7.78M	0.04%	302

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Skandinaviska Enskilda Banken (SEB)'s CPRX Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 263,353 shares — an estimated $6.14M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CPRX in Q3 2024 and held it in 6 quarters. The position peaked at $19.1M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 263,353 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.14M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 6 quarters.
Skandinaviska Enskilda Banken (SEB)'s Catalyst Pharmaceutical position peaked at $19.1M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.